Novo Nordisk

Novo Nordisk today presented data from the STEER real-world study of evidence gathered from actual patient experiences at the European Society of Cardiology (ESC) Congress 2025 in Madrid, Spain. The STEER study investigated the risk of major adverse cardiovascular events (MACE) with Wegovy® (semaglutide 2.4 mg) compared with tirzepatide treatment in people with overweight or obesity and established CVD without diabetes.1 Compared with tirzepatide, Wegovy® showed a significant 57% greater risk reduction for heart attack, stroke and cardiovascular-related death or death from any cause, in people with overweight or obesity ...